Detalles de la búsqueda
1.
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
Invest New Drugs;
2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833067
2.
Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis.
J Gynecol Oncol;
2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38857908
3.
Quality of care measurement for patients with ovarian cancer in Japan.
J Obstet Gynaecol Res;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697202
4.
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Cancer Med;
13(8): e6980, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38651187
5.
A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
Cancer Chemother Pharmacol;
93(6): 605-616, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38411735
6.
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Melanoma Res;
33(6): 547-552, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696254
7.
The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer.
Cancer Med;
12(11): 12095-12105, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012214
8.
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Cancer;
129(15): 2348-2359, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37080942
9.
Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Jpn J Clin Oncol;
53(2): 105-114, 2023 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36373891
10.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Cancer Sci;
113(11): 3877-3887, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35792064
11.
Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer.
Anticancer Res;
42(7): 3743-3751, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790267
12.
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Eur J Cancer;
168: 108-118, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35500404
13.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
JCO Precis Oncol;
6: e2000368, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35294223
14.
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Breast;
61: 136-144, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34999427
15.
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.
Cancer Res Commun;
2(11): 1426-1435, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36970056
16.
Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
Anticancer Res;
41(12): 6217-6224, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34848476
17.
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Clin Cancer Res;
27(24): 6709-6715, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34593531
18.
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Invest New Drugs;
39(6): 1568-1576, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34160752
19.
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis.
Breast;
58: 50-56, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33901922
20.
Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
In Vivo;
35(2): 1041-1049, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33622900